These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 2306181)

  • 21. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.
    Ross JS; Figge H; Bui HX; del Rosario AD; Jennings TA; Rifkin MD; Fisher HA
    Cancer; 1994 Nov; 74(10):2811-8. PubMed ID: 7954242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ploidy status correlates with outcome in stage B prostate adenocarcinoma.
    Tucci Júnior S; Blumenfeld W; Narayan P
    Braz J Med Biol Res; 1994 Jan; 27(1):25-32. PubMed ID: 8173528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deoxyribonucleic acid ploidy status as no basis for pathologic stage prediction in clinically resectable prostate cancer.
    Egawa S; Satoh T; Iwamura M; Aihara M; Kuwao S; Uchida T; Koshiba K
    Urology; 1996 Apr; 47(4):548-52. PubMed ID: 8638366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between DNA ploidy, glandular differentiation, and tumor spread in human prostate cancer.
    Frankfurt OS; Chin JL; Englander LS; Greco WR; Pontes JE; Rustum YM
    Cancer Res; 1985 Mar; 45(3):1418-23. PubMed ID: 3971384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group.
    van den Ouden D; Tribukait B; Blom JH; Fossa SD; Kurth KH; ten Kate FJ; Heiden T; Wang N; Schroder FH
    J Urol; 1993 Aug; 150(2 Pt 1):400-6. PubMed ID: 8326563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
    Kallakury BV; Sheehan CE; Ambros RA; Fisher HA; Kaufman RP; Ross JS
    Cancer; 1997 Aug; 80(4):753-63. PubMed ID: 9264360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of abnormal diploid DNA histograms in localized prostate cancer and adjacent benign prostatic tissue.
    Deitch AD; Miller GJ; deVere White RW
    Cancer; 1993 Sep; 72(5):1692-700. PubMed ID: 7688657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow cytometric DNA analysis of fresh prostatic resections. Correlation with conventional prognostic parameters in patients with prostate cancer.
    Hussain MH; Powell I; Zaki N; Maciorowski Z; Sakr W; KuKuruga M; Visscher D; Haas GP; Pontes JE; Ensley JF
    Cancer; 1993 Nov; 72(10):3012-9. PubMed ID: 7693326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA ploidy: early malignant lesions.
    Lieber MM
    J Cell Biochem Suppl; 1992; 16H():44-6. PubMed ID: 1289672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA flow cytometry in carcinoma of the prostate for diagnosis, prognosis and study of tumor biology.
    Tribukait B
    Acta Oncol; 1991; 30(2):187-92. PubMed ID: 2029403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic value of deoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma.
    Miller J; Horsfall DJ; Marshall VR; Rao DM; Leong SY
    J Urol; 1991 Jun; 145(6):1192-6. PubMed ID: 2033691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma.
    Centeno BA; Zietman AL; Shipley WU; Sobczak ML; Shipley JW; Preffer FI; Boyle BJ; Colvin RB
    Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):309-15. PubMed ID: 7928459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transitional cell carcinoma of the renal pelvis and ureter: prognostic relevance of nuclear deoxyribonucleic acid ploidy studied by slide cytometry: an 8-year survival time study.
    al-Abadi H; Nagel R
    J Urol; 1992 Jul; 148(1):31-7. PubMed ID: 1613875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure.
    Borre M; Høyer M; Nerstrøm B; Overgaard J
    Prostate; 1998 Sep; 36(4):244-9. PubMed ID: 9719024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA ploidy is stronger than lymph node metastasis as prognostic factor in cervical carcinoma: 10-year results of a prospective study.
    Susini T; Olivieri S; Molino C; Amunni G; Rapi S; Taddei G; Scarselli G
    Int J Gynecol Cancer; 2011 May; 21(4):678-84. PubMed ID: 21412157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma--necessitating multiple site analysis.
    Warzynski MJ; Soechtig CE; Maatman TJ; Goldsmith LC; Grobbel MA; Carothers GG; Shockley KF
    Prostate; 1995 Dec; 27(6):329-35. PubMed ID: 7501545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In treating localized prostate cancer the efficacy of cryoablation is independent of DNA ploidy type.
    Bahn DK; Silverman P; Lee F; Badalament R; Bahn ED; Rewcastle JC
    Technol Cancer Res Treat; 2004 Jun; 3(3):253-7. PubMed ID: 15161318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation.
    Seay TM; Blute ML; Zincke H
    J Urol; 1998 Feb; 159(2):357-64. PubMed ID: 9649239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
    Pollack A; Zagars GK; el-Naggar AK; Terry NH
    Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flow cytometric analysis of localized adenocarcinoma of the prostate: the use of archival DNA analysis in conjunction with pathological grading to predict clinical outcome following radical retropubic prostatectomy.
    Ring KS; Karp FS; Olsson CA; O'Toole K; Bixon R; Benson MC
    Prostate; 1990; 17(2):155-64. PubMed ID: 2399191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.